188 related articles for article (PubMed ID: 35483930)
21. RECIL versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients.
Berzaczy D; Haug A; Staber PB; Raderer M; Kiesewetter B; Jaeger U; Kornauth C; Simonitsch-Klupp I; Mayerhoefer ME
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861433
[TBL] [Abstract][Full Text] [Related]
22. The utility of FDG-PET for managing patients with malignant lymphoma: analysis of data from a single cancer center.
Imataki O; Tamai Y; Yokoe K; Furukawa T; Kawakami K
Intern Med; 2009; 48(17):1509-13. PubMed ID: 19721294
[TBL] [Abstract][Full Text] [Related]
23. Application of Quantitative Indexes of FDG PET to Treatment Response Evaluation in Indolent Lymphoma.
Kim HJ; Lee R; Choi H; Paeng JC; Cheon GJ; Lee DS; Chung JK; Kang KW
Nucl Med Mol Imaging; 2018 Oct; 52(5):342-349. PubMed ID: 30344782
[TBL] [Abstract][Full Text] [Related]
24. Imaging for Staging and Response Assessment in Lymphoma.
Johnson SA; Kumar A; Matasar MJ; Schöder H; Rademaker J
Radiology; 2015 Aug; 276(2):323-38. PubMed ID: 26203705
[TBL] [Abstract][Full Text] [Related]
25. Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma.
Ferrari C; Minoia C; Asabella AN; Nicoletti A; Altini C; Antonica F; Ficco M; Guarini A; Maggialetti N; Rubini G
Hell J Nucl Med; 2014; 17 Suppl 1():40-9. PubMed ID: 24392468
[TBL] [Abstract][Full Text] [Related]
26. Diffusion-weighted MRI for initial staging in Hodgkin`s lymphoma: comparison with FDG PET.
Winzer R; Hoberück S; Zöphel K; Kotzerke J; Brauer T; Hoffmann RT; Platzek I
Eur J Radiol; 2020 Feb; 123():108775. PubMed ID: 31864143
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J; Barrington SF; Belada D; Meignan M; MacEwan R; Owen C; Ptáčník V; Rosta A; Fingerle-Rowson GR; Zhu J; Nielsen T; Sahin D; Hiddemann W; Marcus RE; Davies A;
Lancet Oncol; 2018 Nov; 19(11):1530-1542. PubMed ID: 30309758
[TBL] [Abstract][Full Text] [Related]
28. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
Li F; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):523-7. PubMed ID: 21518522
[TBL] [Abstract][Full Text] [Related]
29. The role of 18F-FDG PET and PET/CT in the evaluation of primary cutaneous lymphoma.
Qiu L; Tu G; Li J; Chen Y
Nucl Med Commun; 2017 Feb; 38(2):106-116. PubMed ID: 27792043
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
31. [Hybrid imaging in lymphoma].
Mayerhöfer ME; Haug A
Radiologe; 2020 May; 60(5):376-385. PubMed ID: 32296856
[TBL] [Abstract][Full Text] [Related]
32. Imaging in staging of malignant lymphoma: a systematic review.
Kwee TC; Kwee RM; Nievelstein RA
Blood; 2008 Jan; 111(2):504-16. PubMed ID: 17916746
[TBL] [Abstract][Full Text] [Related]
33. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers.
Facey K; Bradbury I; Laking G; Payne E
Health Technol Assess; 2007 Oct; 11(44):iii-iv, xi-267. PubMed ID: 17999839
[TBL] [Abstract][Full Text] [Related]
34. Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma.
Al Tabaa Y; Tchernonog E; Faurie P; Cottereau AS; Monjanel H; Bonnet A; Le Gouill S; Gyan E; Ghesquieres H; Mariano-Goulart D; Cartron G
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1705-1709. PubMed ID: 29679112
[TBL] [Abstract][Full Text] [Related]
35. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
36. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
37. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
38. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma.
Cho SF; Chang CC; Liu YC; Chang CS; Hsiao HH; Liu TC; Huang CT; Lin SF
Kaohsiung J Med Sci; 2015 Mar; 31(3):130-7. PubMed ID: 25744235
[TBL] [Abstract][Full Text] [Related]
39.
Verhagen MV; Menezes LJ; Neriman D; Watson TA; Punwani S; Taylor SA; Shankar A; Daw S; Humphries PD
J Nucl Med; 2021 Nov; 62(11):1524-1530. PubMed ID: 33608429
[TBL] [Abstract][Full Text] [Related]
40. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET/CT staging in lymphoma.
Ngeow JYY; Quek RHH; Ng DCE; Hee SW; Tao M; Lim LC; Tan YH; Lim ST
Ann Oncol; 2009 Sep; 20(9):1543-1547. PubMed ID: 19474116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]